IGM Biosciences, Inc. (IGMS)

Market Cap	558.82M
Revenue (ttm)	2.13M
Net Income (ttm)	-246.42M
Shares Out	58.95M
EPS (ttm)	-4.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,893
Open	9.63
Previous Close	9.63
Day's Range	9.38 - 10.19
52-Week Range	3.81 - 17.70
Beta	0.25
Analysts	Buy
Price Target	17.25 (+81.96%)
Earnings Date	May 10, 2024

About IGMS

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prote...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2019
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: IGMS

Financial Performance

In 2023, IGMS's revenue was $2.13 million, an increase of 99.25% compared to the previous year's $1.07 million. Losses were -$246.42 million, 11.4% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is $17.25, which is an increase of 81.96% from the latest price.

Price Target

$17.25

(81.96% upside)

Analyst Consensus: Buy